Riven (Yili) Bu

Riven (Yili) Bu

Associate

Riven (Yili) Bu is a an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law.

While in law school, Riven was a student attorney at Georgetown Law's Civil Rights Clinic, where she provided civil litigation service to underrepresented individuals. Riven also served as an in-house counsel intern for a consulting firm.

In addition to English, Riven is fluent in Mandarin.

Experience

Riven (Yili) Bu is a an associate in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where she practices corporate and securities law.

In addition to English, Riven is fluent in Mandarin.

Education

J.D., Georgetown University Law Center, 2024
Cum Laude
M.S., Management, Richard Ivey School of Business, The University of Western Ontario, 2020
B.A., South China University of Technology, 2018

Admissions

State Bar of California

Credentials

Education

J.D., Georgetown University Law Center, 2024
Cum Laude
M.S., Management, Richard Ivey School of Business, The University of Western Ontario, 2020
B.A., South China University of Technology, 2018

Admissions

State Bar of California

Recent Insights

Client Highlights

On June 1, 2026, Resmed, a medical device company that develops, manufactures, and distributes medical equipment for the diagnosis, treatment, and management of respiratory disorders, announced it has closed on its acquisition of Noctrix Health, a medical device company that developed and manufactures a novel therapy to treat drug-refractory Restless Legs Syndrome (RLS) for $340 million. Wilson Sonsini Goodrich & Rosati advised Noctrix on the transaction.

Learn More

Client Highlights

On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.

Learn More